(MGTX) MeiraGTx Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: KYG596651029

Gene Therapy, Ocular, Neurodegenerative, Xerostomia

Stock: Biotechnology
Age 7.6y
MCap 597m
Avg Vol 411K (3.18M USD)
Beta 0.973
Volatility 74.94%

EPS (Earnings per Share)

EPS (Earnings per Share) of MGTX over the last years for every Quarter: "2020-12": -0.25, "2021-03": -0.54, "2021-06": -0.46, "2021-09": -0.59, "2021-12": -0.22, "2022-03": -0.7, "2022-06": -0.76, "2022-09": -0.83, "2022-12": -0.6, "2023-03": -0.62, "2023-06": -0.53, "2023-09": -0.74, "2023-12": -0.42, "2024-03": -0.32, "2024-06": -0.76, "2024-09": -0.55, "2024-12": -0.5, "2025-03": -0.51, "2025-06": -0.48, "2025-09": -0.62, "2025-12": 0,
EPS CAGR: 51.37%
EPS Trend: 60.6%
Last SUE: 3.09
Qual. Beats: 1

Revenue

Revenue of MGTX over the last years for every Quarter: 2020-12: 3.787872, 2021-03: 4.595, 2021-06: 5.116, 2021-09: 6.947, 2021-12: 21.043, 2022-03: 5.633, 2022-06: 10.759, 2022-09: 4.816, 2022-12: -5.288, 2023-03: 3.334, 2023-06: 3.54, 2023-09: 5.103, 2023-12: 2.04, 2024-03: 0.697, 2024-06: 0.282, 2024-09: 10.91, 2024-12: 21.39, 2025-03: 1.926, 2025-06: 3.691, 2025-09: 0.41, 2025-12: null,
Rev. CAGR: -65.01%
Rev. Trend: -16.2%
Last SUE: -0.48
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 74.9%
Value at Risk 5%th 113%
Relative Tail Risk -8.09%
Reward TTM
Sharpe Ratio 0.74
Alpha 14.36
CAGR/Max DD 0.07
Character TTM
Hurst Exponent 0.570
Beta 0.973
Beta Downside 0.991
Drawdowns 3y
Max DD 58.14%
Mean DD 28.17%
Median DD 28.37%

Description: MGTX MeiraGTx Holdings December 26, 2025

MeiraGTx Holdings plc (NASDAQ:MGTX) is a clinical-stage biotechnology firm focused on gene-therapy solutions for serious ocular, neurodegenerative, and xerostomia indications. Founded in 2015 and headquartered in New York, the company leverages adeno-associated virus (AAV) vectors to deliver therapeutic genes across a portfolio that includes AAV-AQP1, AAV-GAD, AAV-RPE65, AAV-CNGB3, AAV-CNGA3, and AAV-AIPL1, among others.

Key pipeline milestones include Phase 2 trials for AAV-AQP1 in radiation-induced xerostomia and Sjögren’s syndrome, AAV-GAD in Parkinson’s disease, and AAV-RPE65 for RPE65-associated retinal dystrophy. Recent company filings (Q2 2024) show a cash balance of approximately $115 million, giving a runway of roughly 18 months at current burn rates, and a 2023 R&D expense of $78 million-both metrics that investors watch closely for financing risk. The global gene-therapy market is projected to exceed $15 billion by 2029, driven by rising FDA approvals (e.g., Zolgensma, Luxturna) and expanding payer coverage, which underpins the economic upside of MeiraGTx’s AAV platform.

Strategic collaborations with Johnson & Johnson Innovative Medicine and Hologen Limited provide development and commercialization pathways for retinal and CNS indications, respectively, while the company’s riboswitch and cell-therapy platforms broaden its addressable market beyond ophthalmology. For a deeper quantitative assessment, you may find ValueRay’s analyst toolkit useful for modeling MeiraGTx’s cash-runway sensitivity and market-size upside.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income: -168.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.64 > 0.02 and ΔFCF/TA -29.65 > 1.0
NWC/Revenue: -433.1% < 20% (prev 571.7%; Δ -1005 % < -1%)
CFO/TA -0.61 > 3% & CFO -116.3m > Net Income -168.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 0.22 > 1.5 & < 3
Outstanding Shares: last quarter (80.9m) vs 12m ago 13.00% < -2%
Gross Margin: 41.01% > 18% (prev -0.61%; Δ 4162 % > 0.5%)
Asset Turnover: 11.21% > 50% (prev 4.65%; Δ 6.56% > 0%)
Interest Coverage Ratio: -12.44 > 6 (EBITDA TTM -143.5m / Interest Expense TTM 12.6m)

Altman Z'' -15.00

A: -0.63 (Total Current Assets 34.2m - Total Current Liabilities 152.9m) / Total Assets 189.5m
B: -4.39 (Retained Earnings -831.3m / Total Assets 189.5m)
C: -0.64 (EBIT TTM -156.1m / Avg Total Assets 244.5m)
D: -3.64 (Book Value of Equity -837.6m / Total Liabilities 230.0m)
Altman-Z'' Score: -26.53= D

Beneish M -2.53

DSRI: 0.71 (Receivables 11.8m/8.43m, Revenue 27.4m/13.9m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.55 (AQ_t 0.06 / AQ_t-1 0.04)
SGI: 1.97 (Revenue 27.4m / 13.9m)
TATA: -0.28 (NI -168.7m - CFO -116.3m) / TA 189.5m)
Beneish M-Score: -2.53 = A

ValueRay F-Score (Strict, 0-100) 41.32

1. Piotroski: 2.0pt
2. FCF Yield: -18.05%
3. FCF Margin: data missing
4. Debt/Equity: -2.17
5. Debt/Ebitda: data missing
7. RoE: data missing
8. Revenue Trend: -16.16%
9. EPS Trend: 60.56%

What is the price of MGTX shares?

As of January 23, 2026, the stock is trading at USD 8.31 with a total of 459,511 shares traded.
Over the past week, the price has changed by +8.06%, over one month by +0.12%, over three months by -4.92% and over the past year by +37.58%.

Is MGTX a buy, sell or hold?

MeiraGTx Holdings has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MGTX.
  • Strong Buy: 3
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MGTX price?

Issuer Target Up/Down from current
Wallstreet Target Price 26.8 221.9%
Analysts Target Price 26.8 221.9%
ValueRay Target Price 8.6 3%

MGTX Fundamental Data Overview January 19, 2026

P/E Forward = 1.6147
P/S = 21.7837
P/B = 228.2969
Revenue TTM = 27.4m USD
EBIT TTM = -156.1m USD
EBITDA TTM = -143.5m USD
Long Term Debt = 73.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 76.5m USD (from shortTermDebt, last quarter)
Debt = 88.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 73.2m USD (from netDebt column, last quarter)
Enterprise Value = 670.5m USD (597.2m + Debt 88.1m - CCE 14.8m)
Interest Coverage Ratio = -12.44 (Ebit TTM -156.1m / Interest Expense TTM 12.6m)
EV/FCF = -5.54x (Enterprise Value 670.5m / FCF TTM -121.0m)
FCF Yield = -18.05% (FCF TTM -121.0m / Enterprise Value 670.5m)
FCF Margin = -441.5% (FCF TTM -121.0m / Revenue TTM 27.4m)
Net Margin = -615.3% (Net Income TTM -168.7m / Revenue TTM 27.4m)
Gross Margin = 41.01% ((Revenue TTM 27.4m - Cost of Revenue TTM 16.2m) / Revenue TTM)
Gross Margin QoQ = 23.66% (prev 27.50%)
Tobins Q-Ratio = 3.54 (Enterprise Value 670.5m / Total Assets 189.5m)
Interest Expense / Debt = 3.48% (Interest Expense 3.06m / Debt 88.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -123.3m (EBIT -156.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.22 (Total Current Assets 34.2m / Total Current Liabilities 152.9m)
Debt / Equity = -2.17 (negative equity) (Debt 88.1m / totalStockholderEquity, last quarter -40.6m)
Debt / EBITDA = -0.51 (negative EBITDA) (Net Debt 73.2m / EBITDA -143.5m)
Debt / FCF = -0.60 (negative FCF - burning cash) (Net Debt 73.2m / FCF TTM -121.0m)
Total Stockholder Equity = 15.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -69.00% (Net Income -168.7m / Total Assets 189.5m)
RoE = -1065 % (out of range, set to none) (Net Income TTM -168.7m / Total Stockholder Equity 15.8m)
RoCE = -175.3% (out of range, set to none) (EBIT -156.1m / Capital Employed (Equity 15.8m + L.T.Debt 73.2m))
RoIC = -137.9% (out of range, set to none) (NOPAT -123.3m / Invested Capital 89.5m)
WACC = 8.63% (E(597.2m)/V(685.3m) * Re(9.50%) + D(88.1m)/V(685.3m) * Rd(3.48%) * (1-Tc(0.21)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.82%
Fair Price DCF = unknown (Cash Flow -121.0m)
EPS Correlation: 60.56 | EPS CAGR: 51.37% | SUE: 3.09 | # QB: 1
Revenue Correlation: -16.16 | Revenue CAGR: -65.01% | SUE: -0.48 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.63 | Chg30d=-0.100 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-2.51 | Chg30d=-0.400 | Revisions Net=+0 | Growth EPS=-12.6% | Growth Revenue=+1073.9%

Additional Sources for MGTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle